HEAVY SOLUTION NUPERCAINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for HEAVY SOLUTION NUPERCAINE (HEAVY SOLUTION NUPERCAINE).

How it works

Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.

What the body does with it

Metabolism	Primarily metabolized in the liver via ester hydrolysis (pseudocholinesterase) and N-dealkylation; exhibits biexponential elimination with a terminal half-life of approximately 2-4 hours. Metabolites are excreted renally.
Excretion	Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Half-life	Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Protein binding	Approximately 95% bound to plasma proteins, primarily alpha1-acid glycoprotein and albumin.
Volume of Distribution	Vd is 0.6-1.2 L/kg (mean 0.9 L/kg), indicating moderate tissue distribution. Higher Vd in neonates (1.5-2.0 L/kg).
Bioavailability	Not applicable for IV administration (100%). Intrathecal: 100% (direct CNS delivery). Epidural: 60-80% systemic absorption due to vascular uptake. Topical: negligible systemic bioavailability.
Onset of Action	Intrathecal: 5-10 minutes for surgical anesthesia. Epidural: 15-20 minutes for analgesia/anesthesia. Topical: 30-60 seconds for corneal anesthesia.
Duration of Action	Intrathecal: 2-4 hours of surgical anesthesia; prolonged with epinephrine (3-5 h). Epidural: 1.5-3 hours. Topical corneal: 20-30 minutes.

Classification & Brands

Dosing & administration

Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.

Dosage form	INJECTABLE
Renal impairment	No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for systemic accumulation.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to decreased metabolism.
Pediatric use	Not recommended; safety and efficacy not established. If used, dose should be individualized based on weight and clinical response.
Geriatric use	Reduce dose by 20-50% due to increased sensitivity and reduced clearance; monitor closely for hypotension and prolonged block.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for HEAVY SOLUTION NUPERCAINE (HEAVY SOLUTION NUPERCAINE).

Breastfeeding	Dibucaine is excreted into breast milk in low amounts; M/P ratio not established for heavy solution. Oral bioavailability is low, so risk to infant is minimal. Use with caution due to potential procedural stress.
Teratogenic Risk	Heavy Solution Nupercaine (dibucaine) is a potent amide local anesthetic. In the first trimester, there is limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: risk of fetal bradycardia and hypoxia due to placental transfer. High doses may cause neonatal CNS depression. Not associated with major malformations at standard doses.

Warnings & precautions

■ FDA Black Box Warning

WARNING: RISK OF CARDIAC ARREST AND DEATH WITH INTRAVASCULAR INJECTION. Accidental intravascular injection may result in cardiac arrest or sudden death due to severe cardiotoxicity. Resuscitative equipment and personnel must be immediately available. Use only with continuous monitoring and in settings prepared for emergency resuscitation.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to dibucaine or other amide local anesthetics","Shock or severe hypotension","Infection at the injection site","Severe coagulopathy or anticoagulant therapy (for neuraxial administration)","Adolescent or pediatric patients (safety not established)"]

Clinical Precautions

Precautions

["Risk of systemic toxicity from accidental intravascular injection or overdose; monitor vital signs continuously.","May cause methemoglobinemia, especially with prolonged use or high doses; treat with methylene blue if symptomatic.","Use with caution in patients with hepatic impairment, renal dysfunction, or history of seizures.","Elderly and debilitated patients require dose reduction due to increased susceptibility to adverse effects.","Avoid use in patients with allergy to amide local anesthetics."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

HEAVY SOLUTION NUPERCAINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for HEAVY SOLUTION NUPERCAINE (HEAVY SOLUTION NUPERCAINE).

How it works

What the body does with it

Metabolism	Primarily metabolized in the liver via ester hydrolysis (pseudocholinesterase) and N-dealkylation; exhibits biexponential elimination with a terminal half-life of approximately 2-4 hours. Metabolites are excreted renally.
Excretion	Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Half-life	Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Protein binding	Approximately 95% bound to plasma proteins, primarily alpha1-acid glycoprotein and albumin.
Volume of Distribution	Vd is 0.6-1.2 L/kg (mean 0.9 L/kg), indicating moderate tissue distribution. Higher Vd in neonates (1.5-2.0 L/kg).
Bioavailability	Not applicable for IV administration (100%). Intrathecal: 100% (direct CNS delivery). Epidural: 60-80% systemic absorption due to vascular uptake. Topical: negligible systemic bioavailability.
Onset of Action	Intrathecal: 5-10 minutes for surgical anesthesia. Epidural: 15-20 minutes for analgesia/anesthesia. Topical: 30-60 seconds for corneal anesthesia.
Duration of Action	Intrathecal: 2-4 hours of surgical anesthesia; prolonged with epinephrine (3-5 h). Epidural: 1.5-3 hours. Topical corneal: 20-30 minutes.

Classification & Brands

Dosing & administration

Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.

Dosage form	INJECTABLE
Renal impairment	No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for systemic accumulation.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to decreased metabolism.
Pediatric use	Not recommended; safety and efficacy not established. If used, dose should be individualized based on weight and clinical response.
Geriatric use	Reduce dose by 20-50% due to increased sensitivity and reduced clearance; monitor closely for hypotension and prolonged block.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for HEAVY SOLUTION NUPERCAINE (HEAVY SOLUTION NUPERCAINE).

Breastfeeding	Dibucaine is excreted into breast milk in low amounts; M/P ratio not established for heavy solution. Oral bioavailability is low, so risk to infant is minimal. Use with caution due to potential procedural stress.
Teratogenic Risk	Heavy Solution Nupercaine (dibucaine) is a potent amide local anesthetic. In the first trimester, there is limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: risk of fetal bradycardia and hypoxia due to placental transfer. High doses may cause neonatal CNS depression. Not associated with major malformations at standard doses.